Anti-Calcification Effects of Immortalized Human Adipose Tissue-Derived Mesenchymal Stem/Stromal Cell (HATMSC2) Secretome in an In Vitro Model of Vascular Calcification
- 1Laboratory of Biology of Stem and Neoplastic Cells, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wroclaw, Poland
Abstract
Vascular calcification (VC) is a very common complication associated with aging, chronic kidney disease, diabetes, and atherosclerosis, predicting cardiovascular morbidity and mortality, but remains largely resistant to current therapies. This study investigated the anti-calcification properties of a secretome derived from a human adipose tissue-derived mesenchymal stem/stromal cell line (HATMSC2) using an in vitro model of vascular smooth muscle cell (VSMC) calcification. VSMCs were cultured in both inorganic and organic calcification media with or without HATMSC2 secretome supplementation (50 μg/mL). Calcium deposition was assessed with Alizarin Red S staining, while osteogenic markers (RUNX2, OPN, OSX, COL-1, OCN) and contractile marker α-SMA were evaluated with Western blot and RT-PCR. The HATMSC2 secretome significantly reduced calcium deposits and suppressed the upregulation of osteogenic markers in the organic calcification model, preventing osteogenic transdifferentiation. Furthermore, the secretome significantly decreased the adhesion of the THP-1 monocyte to VSMCs under calcification-promoting conditions, confirming its immunomodulatory effects. The detection of BMP antagonists, GREM1 and CHRDL1, MGP (anti-calcification factor), and the BMP signaling agonist BMP-7 in the HATMSC2-derived secretome indicates factors that may potentially contribute to its anti-calcification activity. These findings are consistent with the modulation of osteogenic signaling pathways; however, the precise molecular mechanisms and the individual contribution of the identified proteins require further functional validation.
Related
- Pilot intraindividual secretome profiling of adipose-derived stem cells in multiple symmetric lipomatosis
- TMEM174 deficiency reduces longevity by promoting phosphate-driven vascular calcification
- Nutritional Modulation of the Immuno–Biomineral Interface: From Vascular Calcification to a Hypothesis-Generating Framework for Tumor-Associated Biomineralization
- Progress on the related mechanisms of vascular calcification in autogenous arteriovenous fistula in hemodialysis patients
- Immobilzation‐Induced Muscle Atrophy Exacerbates Vascular Calcification and Abdominal Aortic Aneurysms Through Irisin Downregulation
BibTeX
@article{piotrowska2026anticalcification,
title = {{Anti-Calcification Effects of Immortalized Human Adipose Tissue-Derived Mesenchymal Stem/Stromal Cell (HATMSC2) Secretome in an In Vitro Model of Vascular Calcification}},
author = {Paulina Piotrowska and Honorata Kraskiewicz and Jolanta Lis-Kuberka and Aleksandra Klimczak},
journal = {Cells},
year = {2026},
month = oct,
doi = {10.3390/cells15211925},
url = {https://www.mdpi.com/2073-4409/15/21/1925},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Anti-Calcification Effects of Immortalized Human Adipose Tissue-Derived Mesenchymal Stem/Stromal Cell (HATMSC2) Secretome in an In Vitro Model of Vascular Calcification
AU - Paulina Piotrowska
AU - Honorata Kraskiewicz
AU - Jolanta Lis-Kuberka
AU - Aleksandra Klimczak
PY - 2026
DA - 2026/10/23
JO - Cells
DO - 10.3390/cells15211925
UR - https://www.mdpi.com/2073-4409/15/21/1925
AB - Vascular calcification (VC) is a very common complication associated with aging, chronic kidney disease, diabetes, and atherosclerosis, predicting cardiovascular morbidity and mortality, but remains largely resistant to current therapies. This study investigated the anti-calcification properties of a secretome derived from a human adipose tissue-derived mesenchymal stem/stromal cell line (HATMSC2) using an in vitro model of vascular smooth muscle cell (VSMC) calcification. VSMCs were cultured in both inorganic and organic calcification media with or without HATMSC2 secretome supplementation (50 μg/mL). Calcium deposition was assessed with Alizarin Red S staining, while osteogenic markers (RUNX2, OPN, OSX, COL-1, OCN) and contractile marker α-SMA were evaluated with Western blot and RT-PCR. The HATMSC2 secretome significantly reduced calcium deposits and suppressed the upregulation of osteogenic markers in the organic calcification model, preventing osteogenic transdifferentiation. Furthermore, the secretome significantly decreased the adhesion of the THP-1 monocyte to VSMCs under calcification-promoting conditions, confirming its immunomodulatory effects. The detection of BMP antagonists, GREM1 and CHRDL1, MGP (anti-calcification factor), and the BMP signaling agonist BMP-7 in the HATMSC2-derived secretome indicates factors that may potentially contribute to its anti-calcification activity. These findings are consistent with the modulation of osteogenic signaling pathways; however, the precise molecular mechanisms and the individual contribution of the identified proteins require further functional validation.
SN - 2073-4409
ER -